Caption Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.67M Buy
9,400
+9,200
+4,600% +$4.08M 0.02% 608
2026
Q1
$89.3K Buy
+200
New +$93.3K ﹤0.01% 1401
2024
Q2
Sell
-3,480
Closed -$1.45M 1541
2024
Q1
$1.45M Buy
+3,480
New +$1.47M 0.02% 637
2022
Q2
Sell
-48,358
Closed -$12.6M 1864
2022
Q1
$12.6M Buy
48,358
+41,958
+656% +$9.96M 0.15% 161
2021
Q4
$1.41M Sell
6,400
-3,400
-35% -$661K 0.02% 918
2021
Q3
$1.78M Buy
+9,800
New +$1.91M 0.02% 811

Other funds holding VRTX

Caption Management's VRTX Position: Q2 2026 in Review

Caption Management increased its Vertex Pharmaceuticals (VRTX) stake by 4,600% in Q2 2026, buying an estimated $4.08M and bringing the position to 9,400 shares worth $4.67M. The position accounts for 0.02% of the portfolio, ranked #608.

Caption Management first reported a position in VRTX in Q3 2021 and has held it in 6 quarters since. The position peaked at $12.6M in Q1 2022. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Caption Management held 9,400 shares of Vertex Pharmaceuticals worth $4.67M as of Q2 2026.
  • Caption Management bought 9,200 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.08M.
  • Vertex Pharmaceuticals made up 0.02% of Caption Management's portfolio in Q2 2026, its #608 holding.
  • Caption Management first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 6 quarters since.
  • Caption Management's Vertex Pharmaceuticals position peaked at $12.6M in Q1 2022.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.